Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 9, 2015, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $650.00 to $360,000,000.00.

Highlighted Stocks Traded by Insiders:

GAIN Capital Holdings (GCAP) - FREE Research Report

Scott Jeffrey, who is Chief Operating Officer at GAIN Capital Holdings, sold 5,025 shares at $9.72 on March 9, 2015. Following this transaction, the Chief Operating Officer owned 57,325 shares meaning that the stake was reduced by 8.06% with the 5,025-share transaction.

The shares most recently traded at $10.04, up $0.32, or 3.15% since the insider transaction. Historical insider transactions for GAIN Capital Holdings go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 38,927
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 95,927
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 166,527

The average volume for GAIN Capital Holdings has been 391,600 shares per day over the past 30 days. GAIN Capital Holdings has a market cap of $430.9 million and is part of the financial sector and financial services industry. Shares are up 12.53% year-to-date as of the close of trading on Monday.

GAIN Capital Holdings, Inc., together with its subsidiaries, provides trading services and solutions to retail and institutional customers worldwide. The stock currently has a dividend yield of 2%. The company has a P/E ratio of 14.1. Currently, there are 2 analysts who rate GAIN Capital Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GCAP - FREE

TheStreet Quant Ratings

rates GAIN Capital Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

GAIN Capital Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Halozyme Therapeutics (HALO) - FREE Research Report

Kelley Kenneth J, who is Director at Halozyme Therapeutics, sold 40,000 shares at $15.33 on March 9, 2015. Following this transaction, the Director owned 194,876 shares meaning that the stake was reduced by 17.03% with the 40,000-share transaction.

The shares most recently traded at $15.39, up $0.06, or 0.36% since the insider transaction. Historical insider transactions for Halozyme Therapeutics go as follows:

  • 4-Week # shares bought: 75,000
  • 12-Week # shares bought: 75,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 75,000
  • 24-Week # shares sold: 10,000

The average volume for Halozyme Therapeutics has been 1.9 million shares per day over the past 30 days. Halozyme Therapeutics has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 59.38% year-to-date as of the close of trading on Monday.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Currently, there are 3 analysts who rate Halozyme Therapeutics a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HALO - FREE

TheStreet Quant Ratings

rates Halozyme Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally high debt management risk. Get the full

Halozyme Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alimera (ALIM) - FREE Research Report

Eiswirth Richard S Jr, who is COO and CFO at Alimera, bought 10,000 shares at $4.84 on March 9, 2015. Following this transaction, the COO and CFO owned 32,474 shares meaning that the stake was boosted by 44.5% with the 10,000-share transaction.

The shares most recently traded at $5.04, up $0.20, or 3.97% since the insider transaction. Historical insider transactions for Alimera go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 69,918

The average volume for Alimera has been 182,500 shares per day over the past 30 days. Alimera has a market cap of $226.4 million and is part of the health care sector and drugs industry. Shares are down 7.76% year-to-date as of the close of trading on Monday.

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. Currently, there are 2 analysts who rate Alimera a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALIM - FREE

TheStreet Quant Ratings

rates Alimera as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Alimera Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null